Immunotherapy treatments approved for small cell lung cancer
First Line (as your first treatment)
The following immunotherapies are approved as first treatment:
- Imfinzi (durvalumab, a PD-L1 Inhibitor) – approved for SCLC patients has been approved for patients in combination with chemotherapy.
- Tecentriq (atezolizumab, a PD-L1 Inhibitor) – approved for SCLC patients has been approved for patients in combination with chemotherapy.
Click here for answers to frequently asked questions about immunotherapy for lung cancer.